Humana Inc.
HUM
$177.83
+0.50%
Humana Inc. is one of the largest private health insurers in the United States, specializing in government-sponsored programs like Medicare and Medicaid. The company has built a strong niche in this sector and also provides complementary healthcare services, including primary care and pharmacy benefit management.…
HUM
Humana Inc.
$177.83
Investment Opinion: Should I buy HUM Today?
Based on a synthesis of the technical collapse, fundamental deterioration, low valuation, and mixed analyst outlook, the objective assessment is a Hold. The current price likely reflects the known bad news, and the low valuation provides a margin of safety, but the lack of a clear catalyst for a near-term operational turnaround and persistent negative momentum warrant caution. Investors should wait for concrete signs of profitability stabilization before considering a new position.
Sign up to view all
HUM 12-Month Price Forecast
The data presents a stark contradiction: catastrophic recent performance against a backdrop of a strong business model and optimistic forward estimates. The probabilities are weighted towards a base-case recovery, but the path is highly uncertain, justifying a neutral stance with medium confidence.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Humana Inc.'s 12-month outlook, with a consensus price target around $231.18 and implied upside of +30.0% versus the current price.
Average Target
$231.18
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$142 - $231
Analyst target range
A consensus of six analysts provides estimates, with an average EPS forecast of $41.63 and average revenue forecast of $204.4 billion. Recent institutional ratings show a mix of opinions, including 'Buy' from Jefferies and Guggenheim, 'Sell' from Goldman Sachs, and several 'Hold' or 'Neutral' ratings from firms like Barclays, Wells Fargo, and UBS, indicating cautious sentiment following recent performance.
Bulls vs Bears: HUM Investment Factors
Humana presents a classic value trap scenario. The stock trades at historically low valuation multiples following a severe price collapse, driven by a dramatic deterioration in profitability. However, its strong market position in government healthcare programs and analyst forecasts for an earnings recovery provide a potential foundation for a turnaround, making it a high-risk, high-potential-reward situation.
Bullish
- Strong Market Position: Leading private health insurer in US with niche in government programs.
- Attractive Valuation Multiples: Low PS ratio of 0.24 and EV/Sales of 0.11 suggest undervaluation.
- Analyst EPS Growth Forecast: Consensus EPS estimate of $41.63 indicates expected profit recovery.
- Revenue Growth: Latest quarter revenue grew 11.3% year-over-year.
Bearish
- Severe Profitability Deterioration: Q4 2025 net loss of -$796M, net margin of -2.45%.
- Sharp Technical Downtrend: Stock down 47.54% from 52-week high, underperforming S&P 500 by 50%.
- Negative Cash Flow: Operating cash flow turned negative at -$1.65B in Q4 2025.
- Mixed Analyst Sentiment: Recent ratings include Sell (Goldman Sachs) and several Holds.
HUM Technical Analysis
The stock's overall trend has been sharply negative, with a 52-week drawdown of -47.54% and a six-month price decline of -32.43%. The stock has significantly underperformed the broader market, evidenced by a 1-year relative strength of -50.40 against the S&P 500. Short-term performance remains weak, with the stock down 9.00% over the past month and 32.30% over the past three months. This decline is more severe than the S&P 500's respective losses of -5.25% and -4.63% over the same periods. The current price of $173.39 is near the bottom of its 52-week range of $163.11 to $315.35, trading approximately 6.3% above the 52-week low. The stock's beta of 0.415 indicates it has been less volatile than the market during this downtrend.
Beta
0.41
0.41x market volatility
Max Drawdown
-47.5%
Largest decline past year
52-Week Range
$163-$315
Price range past year
Annual Return
-33.1%
Cumulative gain past year
| Period | HUM Return | S&P 500 |
|---|---|---|
| 1m | -2.1% | -3.6% |
| 3m | -32.8% | -4.0% |
| 6m | -37.3% | -2.0% |
| 1y | -33.1% | +16.2% |
| ytd | -32.8% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HUM Fundamental Analysis
Revenue growth showed an 11.3% year-over-year increase in the latest quarter, but profitability has deteriorated sharply. The company reported a net loss of -$796 million for Q4 2025, with a net margin of -2.45%, a significant reversal from positive net income in prior quarters of the year. Financial health shows a debt-to-equity ratio of 0.73, indicating moderate leverage. However, cash flow generation weakened considerably, with operating cash flow turning negative at -$1.65 billion in Q4 2025, although trailing twelve-month free cash flow remains positive at $375 million. Operational efficiency metrics have declined from earlier in the year. Return on Equity (ROE) stands at 6.73%, and Return on Assets (ROA) is 4.3%, reflecting the impact of the recent quarterly loss on annualized figures.
Quarterly Revenue
$32.5B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.11%
Latest Quarter
Free Cash Flow
$375000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HUM Overvalued?
Given the company reported a net loss in the latest quarter, the Price-to-Sales (PS) ratio is a more appropriate valuation metric than the P/E ratio. The current PS ratio is 0.24, and the Enterprise Value-to-Sales (EV/Sales) ratio is 0.11, suggesting the market is valuing the company at a low multiple of its revenue. Peer comparison data is not available in the provided inputs. The forward P/E ratio of 11.34, based on analyst estimates, appears low but reflects significant uncertainty given the recent profitability challenges and negative trailing P/E of 25.97.
PE
26.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1073x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.6x
Enterprise Value Multiple
Investment Risk Disclosure
Humana's risk profile is elevated. The primary risk is operational, evidenced by the sudden swing to a significant net loss and negative operating cash flow in Q4 2025, which raises questions about cost management and pricing power within its core Medicare/Medicaid markets. Financial risk is moderate, with a debt-to-equity of 0.73, but the negative cash flow could pressure liquidity if sustained. Market risk is high, as the stock has shown extreme volatility and poor relative strength, indicating a severe loss of investor confidence. Regulatory risk is a constant in the healthcare sector, and any changes to government reimbursement rates could directly impact future profitability. The high short interest (ratio 2.96) suggests a significant portion of the market is betting on further declines.
FAQ
The key risks are operational and financial. The company must reverse the severe profitability decline seen in Q4 2025, where it reported a -$796M net loss. Persistent high medical costs or unfavorable government reimbursement rates pose ongoing threats. Market risk is also high, with the stock in a strong downtrend and underperforming the S&P 500 by over 50% in the past year, indicating weak sentiment.
The 12-month outlook is highly bifurcated. The base case (50% probability) sees a recovery to a range of $180-$250 as the company stabilizes. The bull case (25%) envisions a return towards the $315 high if operations rebound strongly. The bear case (25%) risks a retest of the 52-week low near $163 if losses continue. Analyst consensus EPS is $41.63, which, if achieved, would support a higher price, but recent results cast doubt on that timeline.
Based on traditional sales multiples, HUM appears significantly undervalued. Its Price-to-Sales ratio of 0.24 and EV/Sales of 0.11 are extremely low, suggesting the market is valuing the company at a deep discount to its revenue base. However, this undervaluation is justified by recent fundamental weakness, including a negative net margin and negative operating cash flow. It is a value trap unless operations improve.
HUM is a high-risk proposition, not a straightforward 'good buy.' At a PS ratio of 0.24, it is statistically cheap, but this follows a 47% drawdown and a shocking Q4 net loss of -$796 million. It could be a good buy for deep-value, contrarian investors betting on a turnaround, but most investors should wait for proof of profitability recovery in future earnings reports before considering a position.
HUM is unsuitable for short-term investment given its high volatility and negative momentum. It is only a candidate for long-term investment (3-5 years) for investors who believe in the long-term stability of its Medicare/Medicaid niche and its ability to execute a multi-year turnaround. The current valuation provides a potential long-term entry point, but investors must be prepared for a potentially lengthy and rocky recovery period.